<p>Apellis Pharmaceuticals（納斯達克：APLS - 獲取免費報告）在週五向投資者發佈的報告中，Stifel Nicolaus 將其目標價格從 55.00 美元下調至 48.00 美元，Benzinga 報道。該券商目前對該股票維持 “買入” 評級。Stifel Nicolaus 的目標價格意味着該公司當前價格有 93.22% 的潛在上漲空間。</p>
<ul>
<li>Beam Therapeutics 因基因治療許可付款而大幅上漲</li>
</ul>
<p>其他幾位研究分析師也對該公司發表了評論。William Blair 在週一的報告中重申了對 Apellis Pharmaceuticals 股票的 “跑贏大盤” 評級。Weiss Ratings 在週一的研究報告中重申了對 Apellis Pharmaceuticals 股票的 “賣出（d）” 評級。高盛集團將 Apellis Pharmaceuticals 的評級從 “中性” 下調至 “賣出”，並將其股票目標價從 26.00 美元下調至 18.00 美元，報告日期為 9 月 26 日。瑞穗證券在 11 月 3 日的報告中將 Apellis Pharmaceuticals 的目標價從 24.00 美元下調至 19.00 美元，並對該股票設定了 “中性” 評級。最後，TD Cowen 在 10 月 31 日的研究報告中將 Apellis Pharmaceuticals 的目標價從 50.00 美元下調至 45.00 美元，並對該股票設定了 “買入” 評級。共有 11 位股票研究分析師對該股票給予了買入評級，7 位給予了持有評級，2 位給予了賣出評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “持有”，共識目標價為 33.94 美元。</p>
<p><strong>查看我們最新的 APLS 研究報告</strong></p>
<h2>Apellis Pharmaceuticals 股票下跌 1.4%</h2>
<ul>
<li>小型股是否預示着市場下跌？</li>
</ul>
<p>APLS 股票在週五開盤價為 24.84 美元。該公司的市值為 31.4 億美元，市盈率為 78.97，貝塔值為 0.37。Apellis Pharmaceuticals 的 52 周低點為 16.10 美元，52 周高點為 35.57 美元。該公司的債務與股本比率為 0.90，速動比率為 3.10，流動比率為 3.54。該股票的 50 日移動平均線為 23.05 美元，200 日移動平均線為 22.56 美元。</p>
<p>Apellis Pharmaceuticals（納斯達克：APLS - 獲取免費報告）最近在 10 月 30 日（星期四）發佈了其財報。該公司報告本季度每股收益為 1.67 美元，超出市場共識預期的 1.03 美元，超出幅度為 0.64 美元。Apellis Pharmaceuticals 的淨利潤率為 4.43%，股本回報率為 18.94%。該公司本季度的收入為 4.5858 億美元，而市場共識預期為 3.6458 億美元。去年同期，該公司每股收益為（0.46）美元。該公司的收入同比增長了 133.0%。作為一個整體，股票研究分析師預測 Apellis Pharmaceuticals 在本年度將發佈每股收益為-1.7 美元。</p>
<h2>Apellis Pharmaceuticals 的內部買賣情況</h2>
<p>在相關消息中，首席財務官 Timothy Eugene Sullivan 在 10 月 21 日（星期二）出售了 10,000 股 Apellis Pharmaceuticals 股票。該股票以平均價格 28.03 美元出售，總交易額為 280,300.00 美元。交易後，首席財務官直接持有該公司 110,936 股股票，估值約為 3,109,536.08 美元。此次交易使其持股比例減少了 8.27%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，首席法律顧問 David O. Watson 在 12 月 16 日（星期二）出售了 5,000 股該公司的股票。該股票以平均價格 24.49 美元出售，總價值為 122,450.00 美元。交易後，首席法律顧問持有該公司 103,730 股股票，估值約為 2,540,347.70 美元。此次交易使其持股比例減少了 4.60%。該銷售的 SEC 文件提供了更多信息。在過去的 90 天裏，內部人士出售了 56,092 股公司股票，價值為 1,366,652 美元。內部人士持有該公司 6.50% 的股份。</p>
<h2>機構投資者對 Apellis Pharmaceuticals 的看法</h2>
<p>機構投資者最近買入和賣出了該公司的股票。Parallel Advisors LLC 在第二季度將其在 Apellis Pharmaceuticals 的持股比例提高了 80.0%。Parallel Advisors LLC 目前持有該公司 1,924 股股票，價值 33,000 美元，此前在上個季度又購買了 855 股。Jones Financial Companies Lllp 在第三季度將其在 Apellis Pharmaceuticals 的持股比例提高了 206.8%。Jones Financial Companies Lllp 目前持有該公司 2,037 股股票，價值 46,000 美元，此前在上個季度又購買了 1,373 股。Osaic Holdings Inc.在第二季度將其在 Apellis Pharmaceuticals 的持股比例提高了 141.2%。Osaic Holdings Inc.目前持有該公司 2,682 股股票，價值 47,000 美元，此前在該期間又收購了 1,570 股。Allworth Financial LP 在第三季度將其在 Apellis Pharmaceuticals 的持股比例提高了 64.1%。Allworth Financial LP 目前持有該公司 2,194 股股票，價值 50,000 美元，此前在該期間又購買了 857 股。最後，Quantbot Technologies LP 在第三季度購買了 Apellis Pharmaceuticals 的新股份，價值 64,000 美元。對沖基金和其他機構投資者持有該公司 96.29% 的股份。</p>
<h2>關於 Apellis Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Apellis Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用於治療陣發性夜間血紅蛋白尿、C3 腎小管病和免疫複合物膜增生性腎小管炎，以及與造血幹細胞移植相關的血栓性微血管病；並提供 SYFOVRE 用於治療與年齡相關的黃斑變性和地理性萎縮（GA）引起的地理性萎縮。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，優於 Apellis Pharmaceuticals</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>Rocket Lab 的強勁反彈：近期動能背後的原因</li>
<li>投資石油股票的方式和原因</li>
<li>Jabil 在雷達下飛行——但可能會迎來 50% 的激增</li>
<li>消費者非必需品股票解析</li>
<li>高通的巨大反彈有一個隱患——這隻股票能否繼續上漲？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Apellis Pharmaceuticals 嗎？</h2>
<p>在考慮 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Apellis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Apellis Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

APLS

<p>Stifel Nicolaus 將 Apellis Pharmaceuticals 的目標股價從 55 美元下調至 48 美元，維持 “買入” 評級。該股票從當前價格來看，潛在上漲幅度為 93.22%。其他分析師的評級則不一，普遍維持 “持有” 評級，目標股價為 33.94 美元。Apellis 報告了強勁的收益，收入同比增長 133%。內部交易活動包括首席財務官和總法律顧問的大量股票出售</p>

<p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) had its target price lowered by Stifel Nicolaus from $55.00 to $48.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the stock. Stifel Nicolaus' target price points to a potential upside of 93.22% from the company's current price.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（納斯達克：APLS - 獲取免費報告）在週五向投資者發佈的報告中，Stifel Nicolaus 將其目標價格從 55.00 美元下調至 48.00 美元，Benzinga 報道。該券商目前對該股票維持 “買入” 評級。Stifel Nicolaus 的目標價格意味着該公司當前價格有 93.22% 的潛在上漲空間。</p>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治療許可付款而大幅上漲</li>
</ul>
</div><p>Several other research analysts have also commented on the company. William Blair reissued an &#34;outperform&#34; rating on shares of Apellis Pharmaceuticals in a report on Monday. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Apellis Pharmaceuticals in a research note on Monday. The Goldman Sachs Group cut Apellis Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;sell&#34; rating and cut their price objective for the stock from $26.00 to $18.00 in a report on Friday, September 26th. Mizuho decreased their price objective on Apellis Pharmaceuticals from $24.00 to $19.00 and set a &#34;neutral&#34; rating on the stock in a report on Monday, November 3rd. Finally, TD Cowen decreased their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, October 31st. Eleven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $33.94.</p>
<div class="lb-trans"><p>其他幾位研究分析師也對該公司發表了評論。William Blair 在週一的報告中重申了對 Apellis Pharmaceuticals 股票的 “跑贏大盤” 評級。Weiss Ratings 在週一的研究報告中重申了對 Apellis Pharmaceuticals 股票的 “賣出（d）” 評級。高盛集團將 Apellis Pharmaceuticals 的評級從 “中性” 下調至 “賣出”，並將其股票目標價從 26.00 美元下調至 18.00 美元，報告日期為 9 月 26 日。瑞穗證券在 11 月 3 日的報告中將 Apellis Pharmaceuticals 的目標價從 24.00 美元下調至 19.00 美元，並對該股票設定了 “中性” 評級。最後，TD Cowen 在 10 月 31 日的研究報告中將 Apellis Pharmaceuticals 的目標價從 50.00 美元下調至 45.00 美元，並對該股票設定了 “買入” 評級。共有 11 位股票研究分析師對該股票給予了買入評級，7 位給予了持有評級，2 位給予了賣出評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “持有”，共識目標價為 33.94 美元。</p>
</div><p><strong>View Our Latest Research Report on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 APLS 研究報告</strong></p>
</div><h2>Apellis Pharmaceuticals Stock Down 1.4%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票下跌 1.4%</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示着市場下跌？</li>
</ul>
</div><p>APLS stock opened at $24.84 on Friday. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of 78.97 and a beta of 0.37. Apellis Pharmaceuticals has a fifty-two week low of $16.10 and a fifty-two week high of $35.57. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock has a fifty day moving average of $23.05 and a 200-day moving average of $22.56.</p>
<div class="lb-trans"><p>APLS 股票在週五開盤價為 24.84 美元。該公司的市值為 31.4 億美元，市盈率為 78.97，貝塔值為 0.37。Apellis Pharmaceuticals 的 52 周低點為 16.10 美元，52 周高點為 35.57 美元。該公司的債務與股本比率為 0.90，速動比率為 3.10，流動比率為 3.54。該股票的 50 日移動平均線為 23.05 美元，200 日移動平均線為 22.56 美元。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter last year, the company earned ($0.46) earnings per share. The company's revenue was up 133.0% on a year-over-year basis. As a group, equities research analysts predict that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（納斯達克：APLS - 獲取免費報告）最近在 10 月 30 日（星期四）發佈了其財報。該公司報告本季度每股收益為 1.67 美元，超出市場共識預期的 1.03 美元，超出幅度為 0.64 美元。Apellis Pharmaceuticals 的淨利潤率為 4.43%，股本回報率為 18.94%。該公司本季度的收入為 4.5858 億美元，而市場共識預期為 3.6458 億美元。去年同期，該公司每股收益為（0.46）美元。該公司的收入同比增長了 133.0%。作為一個整體，股票研究分析師預測 Apellis Pharmaceuticals 在本年度將發佈每股收益為-1.7 美元。</p>
</div><h2>Insider Buying and Selling at Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 的內部買賣情況</h2>
</div><p>In related news, CFO Timothy Eugene Sullivan sold 10,000 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00. Following the transaction, the chief financial officer directly owned 110,936 shares in the company, valued at approximately $3,109,536.08. The trade was a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $24.49, for a total value of $122,450.00. Following the transaction, the general counsel owned 103,730 shares of the company's stock, valued at approximately $2,540,347.70. This trade represents a 4.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 56,092 shares of company stock valued at $1,366,652. Insiders own 6.50% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Timothy Eugene Sullivan 在 10 月 21 日（星期二）出售了 10,000 股 Apellis Pharmaceuticals 股票。該股票以平均價格 28.03 美元出售，總交易額為 280,300.00 美元。交易後，首席財務官直接持有該公司 110,936 股股票，估值約為 3,109,536.08 美元。此次交易使其持股比例減少了 8.27%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，首席法律顧問 David O. Watson 在 12 月 16 日（星期二）出售了 5,000 股該公司的股票。該股票以平均價格 24.49 美元出售，總價值為 122,450.00 美元。交易後，首席法律顧問持有該公司 103,730 股股票，估值約為 2,540,347.70 美元。此次交易使其持股比例減少了 4.60%。該銷售的 SEC 文件提供了更多信息。在過去的 90 天裏，內部人士出售了 56,092 股公司股票，價值為 1,366,652 美元。內部人士持有該公司 6.50% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Apellis Pharmaceuticals 的看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock valued at $33,000 after buying an additional 855 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company's stock valued at $46,000 after purchasing an additional 1,373 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company's stock valued at $47,000 after acquiring an additional 1,570 shares during the period. Allworth Financial LP boosted its position in shares of Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company's stock valued at $50,000 after buying an additional 857 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in Apellis Pharmaceuticals in the third quarter worth $64,000. Hedge funds and other institutional investors own 96.29% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該公司的股票。Parallel Advisors LLC 在第二季度將其在 Apellis Pharmaceuticals 的持股比例提高了 80.0%。Parallel Advisors LLC 目前持有該公司 1,924 股股票，價值 33,000 美元，此前在上個季度又購買了 855 股。Jones Financial Companies Lllp 在第三季度將其在 Apellis Pharmaceuticals 的持股比例提高了 206.8%。Jones Financial Companies Lllp 目前持有該公司 2,037 股股票，價值 46,000 美元，此前在上個季度又購買了 1,373 股。Osaic Holdings Inc.在第二季度將其在 Apellis Pharmaceuticals 的持股比例提高了 141.2%。Osaic Holdings Inc.目前持有該公司 2,682 股股票，價值 47,000 美元，此前在該期間又收購了 1,570 股。Allworth Financial LP 在第三季度將其在 Apellis Pharmaceuticals 的持股比例提高了 64.1%。Allworth Financial LP 目前持有該公司 2,194 股股票，價值 50,000 美元，此前在該期間又購買了 857 股。最後，Quantbot Technologies LP 在第三季度購買了 Apellis Pharmaceuticals 的新股份，價值 64,000 美元。對沖基金和其他機構投資者持有該公司 96.29% 的股份。</p>
</div><h2>About Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Apellis Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療自身免疫和炎症疾病的化合物。它提供 EMPAVELI 用於治療陣發性夜間血紅蛋白尿、C3 腎小管病和免疫複合物膜增生性腎小管炎，以及與造血幹細胞移植相關的血栓性微血管病；並提供 SYFOVRE 用於治療與年齡相關的黃斑變性和地理性萎縮（GA）引起的地理性萎縮。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Rocket Lab's Sharp Rebound: What's Behind the Recent Momentum</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Jabil Is Flying Under the Radar—But a 50% Surge May Be Coming</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Qualcomm’s Monster Rally Has a Catch—Can the Stock Keep Climbing?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，優於 Apellis Pharmaceuticals</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>Rocket Lab 的強勁反彈：近期動能背後的原因</li>
<li>投資石油股票的方式和原因</li>
<li>Jabil 在雷達下飛行——但可能會迎來 50% 的激增</li>
<li>消費者非必需品股票解析</li>
<li>高通的巨大反彈有一個隱患——這隻股票能否繼續上漲？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Apellis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Apellis Pharmaceuticals 並不在名單上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Apellis Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Stifel Nicolaus 將 Apellis Pharmaceuticals（NASDAQ:APLS）的目標股價下調至 48.00 美元